ACE inhibitors and diabetics with albuminuria. The DIABHYCAR Study Group

BACT-URIE: A Novel Score Integrating Bacteriuria to Predict Infective Endocarditis in Patients With Staphylococcus aureus Bacteremia.

Open forum infectious diseases·2026

Amputation-free survival in the long-term follow-up and gender-related characteristics in patients revascularized for critical limb ischemia.

Journal de medecine vasculaire·2023

Peri-procedural complications following endovascular revascularization for critical limb ischemia.

Journal de medecine vasculaire·2022

Factors associated with psychological symptoms in hospital workers of a French hospital during the COVID-19 pandemic: Lessons from the first wave.

PloS one·2022

Patients with atherosclerotic peripheral arterial disease have a high risk of lung cancer: Systematic review and meta-analysis of literature.

Journal de medecine vasculaire·2021

Influence of clinical suspicion on CT accuracy of acute mesenteric ischemia: Retrospective study of 362 patients.

European journal of radiology·2021

Izalontamab brengitecan versus platinum-based chemotherapy in EGFR-mutated advanced non-squamous non-small-cell lung cancer after progression on third-generation EGFR tyrosine kinase inhibitors (PANKU-Lung01): a multicentre, randomised, open-label, phase 3 trial in China.

Lancet (London, England)·2026

Sacituzumab tirumotecan versus treatment of physician's choice in previously treated endometrial cancer (TroFuse-005/ENGOT-en23/GOG-3095): a randomised, open-label, phase 3 trial.

Lancet (London, England)·2026

Izalontamab brengitecan for HR+/HER2- breast cancer in China (PANKU-Breast01): a randomised, phase 3 trial.

Lancet (London, England)·2026

First-line pembrolizumab versus carboplatin plus paclitaxel in participants with mismatch repair-deficient advanced or recurrent endometrial cancer (KEYNOTE-C93/GOG-3064/ENGOT-en15): interim analysis of a multicentre, open-label, randomised, active-comparator controlled, phase 3 trial.

Lancet (London, England)·2026

Ruzaltatug rezetecan versus chemotherapy for EGFR-mutated advanced non-small-cell lung cancer progressing after EGFR tyrosine kinase inhibitor therapy (HERON-Lung01): interim analysis of a randomised, open-label, phase 3 trial in China.

Lancet (London, England)·2026

14-day versus 28-day trifluridine-tipiracil plus bevacizumab for refractory metastatic colorectal cancer (PRABITAS): a pragmatic, multicentre, open-label, randomised, phase 3, non-inferiority trial in Japan.

Lancet (London, England)·2026

From LC-MS Metabolomic Profiling to AIEnabled Navigation of NPs Chemical Space: Recent Advances and Emerging Directions.

Chimia·2026

Retention-Guided LC-MS/MS Enables Discovery and Structural Assignment of Trace Steviol Glycosides from in Vitro Glycosylation Reactions.

Journal of agricultural and food chemistry·2026

Cynarin Targets Host CX3CR1 for Dual-Action Prophylaxis against RSV Infection and Pulmonary Pathology.

Journal of agricultural and food chemistry·2026

Evaluation of 3',4'-cyclopropyl monomers for oligonucleotide therapeutic applications.

Organic & biomolecular chemistry·2026

Cell-type-resolved colocalisation prioritises KCNIP2 as a candidate epilepsy drug-target detectable at inhibitory-neuron but not bulk-tissue resolution: a Mendelian randomisation and colocalisation study.

Frontiers in genetics·2026

Recent Advances in Reversed-Phase Liquid Chromatography for Therapeutic Oligonucleotide and Conjugate Characterization: From Ion-Pairing to Green Analytical Approaches.

Analytical science advances·2026

Related Experiment Videos

ACE inhibitors and diabetics with albuminuria. The DIABHYCAR Study Group

Related Concept Videos

BACT-URIE: A Novel Score Integrating Bacteriuria to Predict Infective Endocarditis in Patients With Staphylococcus aureus Bacteremia.

Amputation-free survival in the long-term follow-up and gender-related characteristics in patients revascularized for critical limb ischemia.

Peri-procedural complications following endovascular revascularization for critical limb ischemia.

Factors associated with psychological symptoms in hospital workers of a French hospital during the COVID-19 pandemic: Lessons from the first wave.

Patients with atherosclerotic peripheral arterial disease have a high risk of lung cancer: Systematic review and meta-analysis of literature.

Influence of clinical suspicion on CT accuracy of acute mesenteric ischemia: Retrospective study of 362 patients.

Izalontamab brengitecan versus platinum-based chemotherapy in EGFR-mutated advanced non-squamous non-small-cell lung cancer after progression on third-generation EGFR tyrosine kinase inhibitors (PANKU-Lung01): a multicentre, randomised, open-label, phase 3 trial in China.

Sacituzumab tirumotecan versus treatment of physician's choice in previously treated endometrial cancer (TroFuse-005/ENGOT-en23/GOG-3095): a randomised, open-label, phase 3 trial.

Izalontamab brengitecan for HR+/HER2- breast cancer in China (PANKU-Breast01): a randomised, phase 3 trial.

First-line pembrolizumab versus carboplatin plus paclitaxel in participants with mismatch repair-deficient advanced or recurrent endometrial cancer (KEYNOTE-C93/GOG-3064/ENGOT-en15): interim analysis of a multicentre, open-label, randomised, active-comparator controlled, phase 3 trial.

Ruzaltatug rezetecan versus chemotherapy for EGFR-mutated advanced non-small-cell lung cancer progressing after EGFR tyrosine kinase inhibitor therapy (HERON-Lung01): interim analysis of a randomised, open-label, phase 3 trial in China.

14-day versus 28-day trifluridine-tipiracil plus bevacizumab for refractory metastatic colorectal cancer (PRABITAS): a pragmatic, multicentre, open-label, randomised, phase 3, non-inferiority trial in Japan.

From LC-MS Metabolomic Profiling to AIEnabled Navigation of NPs Chemical Space: Recent Advances and Emerging Directions.

Retention-Guided LC-MS/MS Enables Discovery and Structural Assignment of Trace Steviol Glycosides from in Vitro Glycosylation Reactions.

Cynarin Targets Host CX3CR1 for Dual-Action Prophylaxis against RSV Infection and Pulmonary Pathology.

Evaluation of 3',4'-cyclopropyl monomers for oligonucleotide therapeutic applications.

Cell-type-resolved colocalisation prioritises KCNIP2 as a candidate epilepsy drug-target detectable at inhibitory-neuron but not bulk-tissue resolution: a Mendelian randomisation and colocalisation study.

Recent Advances in Reversed-Phase Liquid Chromatography for Therapeutic Oligonucleotide and Conjugate Characterization: From Ion-Pairing to Green Analytical Approaches.

Related Experiment Videos

ACE inhibitors and diabetics with albuminuria. The DIABHYCAR Study Group

Related Concept Videos

Related Articles